Titchen Thirza, Cranswick Noel, Beggs Sean
Royal Children's Hospital, Parkville, Australia.
Br J Clin Pharmacol. 2005 Jun;59(6):718-23. doi: 10.1111/j.1365-2125.2005.02444.x.
The use of nonsteroidal anti-inflammatory drugs (NSAIDs) in children has rapidly escalated over the last 5 years in Australia. This is primarily as a result of the availability of ibuprofen as an over-the-counter preparation. Several recent, significant adverse drug reactions (ADRs) to NSAIDs, at the Royal Children's Hospital (RCH) in Melbourne, Australia prompted review of all of the RCH reactions reported to these agents over 5 years.
The ADR programme documents both spontaneously reported ADRs and ADRs identified by discharge coding. For this study, reported reactions to aspirin, celecoxib, ibuprofen, indomethacin, naproxen, paracetamol and rofecoxib, for the previous 5-year period, were retrieved from the hospital ADR database.
Nineteen reports of ADRs to NSAIDs and six to paracetamol, in patients aged from 4 months to 22 years (median 10 years) were identified. Reactions were predominantly rash (n = 10), gastrointestinal (n = 5) and respiratory (n = 4) side-effects. These included reports of haematemesis with both celecoxib and ibuprofen. One patient died of severe acute exacerbation of asthma following initiation of rofecoxib.
NSAID exposures are a significant cause of morbidity in children. Both nonselective NSAIDs and the newer COX-2 inhibitors were associated with significant drug reactions. The overall severity of these ADRs highlights the need for vigilant surveillance of ADRs in paediatrics, including both established and newer agents.
在过去5年中,澳大利亚儿童使用非甾体抗炎药(NSAIDs)的情况迅速增加。这主要是由于布洛芬可作为非处方药获得。澳大利亚墨尔本皇家儿童医院(RCH)近期发生了几起严重的NSAIDs药物不良反应(ADR),促使对过去5年向这些药物报告的所有RCH不良反应进行审查。
ADR项目记录了自发报告的ADR和通过出院编码确定的ADR。在本研究中,从医院ADR数据库中检索了过去5年报告的对阿司匹林、塞来昔布、布洛芬、吲哚美辛、萘普生、对乙酰氨基酚和罗非昔布的反应。
确定了19例NSAIDs的ADR报告和6例对乙酰氨基酚的ADR报告,患者年龄从4个月至22岁(中位数10岁)。反应主要为皮疹(n = 10)、胃肠道(n = 5)和呼吸道(n = 4)副作用。其中包括塞来昔布和布洛芬导致呕血的报告。1例患者在开始使用罗非昔布后死于哮喘严重急性加重。
NSAIDs暴露是儿童发病的重要原因。非选择性NSAIDs和新型COX-2抑制剂均与严重药物反应相关。这些ADR的总体严重性凸显了对儿科ADR进行警惕监测的必要性,包括已有的和新型药物。